Skip to main content

ACR 2026: Fibromyalgia Topic Panel

Nov 18, 2026 5:31 am
What stood out in Fibromyalgia at ACR 2026? Join Drs. Bella Mehta, Adela Castro, and Eric Dein for RheumNow’s Fibromyalgia Topic Panel Recap. The panel shares what caught their attention in Orlando and discusses what it could mean for the everyday care of patients living with fibromyalgia.

Transcription

This is an ACR twenty twenty six podcast coming to you from ACR in Orlando. Hope you enjoy it. Great rheumatologists go to great meetings like this. RoomNow live twenty twenty seven is happening January 3031 in Dallas, Texas. Join your colleagues from across the country and around the world for an interactive, engaging, and practice changing event.

Go to roomnow.live to see the full program and register today. Hi, everyone. Welcome to RheumNow, ACR twenty twenty seven convergence topic panel where we gather and talk about one of our favorite topics, fibromyalgia. I'm Jack Cush with RheumNow in Dallas, Texas. I'll ask our esteemed faculty to each introduce themselves.

Eric.

Hi. Eric Dine from Summit, New Jersey.

And Adela.

Hi. I'm Adela Castro from University of Tennessee Memphis.

And Bella.

Hi. I'm Bella Mehta from New York.

Alright. So we're gonna do two rounds of our favorites. I'm gonna begin with doctor Mehta. Bella, what did you like to lead off with?

So I I came across this abstract, which was like a huge meta analysis systematic review. The abstract number is two eight two one. So this was sort of pool data from 29 studies, 33 different evaluation tools for fibromyalgia from 24 countries, about 10,000 patients. So pretty big study for fibromyalgia. And, basically, they looked at how good these tools are that we used, use in clinic to diagnose fibromyalgia.

I think the two key tools that they talked about was the first of the fibromyalgia rapid screening tool, which is like a six question, you know, sort of less than a minute to do it. And then the second tool they talked about a lot was the ACR FSQ based self report instruments, which is a widespread index... Widespread pain index as well as sort of symptom severity scale, which is like looking at fatigue, sleep, cognitive issue, symptom... You know, other somatic symptoms. And sort of the key results was that the sensitivity for first, which is the shorter version of the tool, around 79%.

Specificity was 82%. And then the ACR FSQ based tools, the sensitivity was much higher, like 87%. Specificity was 79%. And, again, these these tools were, like, moderate to fairly similar in terms of how they perform. I think the most, you know, the most that I take away from this is that use these tools for case finding, not diagnosis.

Sort of use them to see who needs more complete fibromyalgia evaluation. So these are questionnaires that you can send out before a patient comes in probably or, you know, in your waiting room. And, again, you know, do not use this. And this is a thing that I always worry about is, like, you put these tools, maybe a patient has spa or like rheumatoid arthritis and then they screen for these things and you bucket them under fibromyalgia. So you want to make sure that you are bucketing or diagnosing inflammatory diseases too, but use them as an add on maybe.

And again, you know, for primary care only, you know, these studies were mostly in subspecialty care, so I don't think that these tools can be widely used, at least with this study, in a primary care setting. Mostly it was like rheumatology setting. Again, some of these studies were like high risk of bias. Again, in meta analysis, there's some really good studies and some okay studies. So I think it's good that they're showing something on such a scale, showing that we can use these quick tools, in clinic before a patient comes in.

Yeah. So, Bella, do you think that this report is going to better inform how clinical trials are done, or is it trying to make the case that these should be done in practice?

I think they're trying to make the case that these can be used in practice for screening purposes. Mean, again, I try to use them, but I don't. So maybe this gives me some more push to start using them.

Adela, what do you think?

So I went to a very good session on diagnosing fibromyalgia by Daniel Claw. And then in this session, he mentioned about the body map. I don't know if you guys have used this before, but it's like a little like sketch of a body and then you give to the patients before you see them and then they pretty much kind of like cross where they are in pain and they pretty much, you know, if you see the body map crossed all over, then, you know, that's suggestive that there's something, you know, like fibromyalgia picture going on. That for me was very helpful to have like a screening tool, especially because I do this body map and I can assess, you know, whenever I'm seeing patients, whenever I see that before seeing them, I know more or less what I'm going to find.

Eric, what do you rely on?

Yeah, I think, you know, it's really history and spending time is where you get the information for this condition. And I think I agree with what Bella said that the screening tools, worry especially in the hands of like a primary care doctor when these quick screening is that there unfortunately has a lot of bias and a lot of anchoring bias that when patients, and I think most of our patients with inflammatory diseases when it's active, will have fatigue, nonspecific pain that can be really hard to disentangle and they may have, you know, nociceptive pain that overlaps with it that may be related to their autoimmune disease as well. But it would be concerning to me if you take a test and you get a quick screen and you end up in the fibromyalgia category investigation stops there. I know that's not the purpose of the screening test, I worry about that in clinical practice.

I just use a survey tool that you can get on RheumNow or use the MD hack. And to me, it's all about the ink. It is a lot of ink on the page. There's a lot of widespread pain going on. I I mean, I like the body map, but...

And I have a version of that, but it's a lot of ink. Or I call this nostalgia when the patient provides so much information and notes that you hurt. You know, the idea here is that, again, there's a low sensitivity, a low threshold to check the box or find the pain. Let's go on and do another one. Eric?

Another study looking at kind of more of the perceptions of fibromyalgia abstract 1554 was looking at a survey of Ontario Canada rheumatologists and comparing a 2026 survey to 2012 and some of the changes over that fourteen year span. In 2026, these rheumatologists said that it was more of a disabling disorder. So seventy one percent in 2026 say that it is disabling versus, fifty eight percent in 2012, so a thirteen percent increase. So even though there's this higher acceptance that fibromyalgia is disabling, it is not felt to be a rheumatologist's concern according to these rheumatologists. So only seven percent felt that it was in the domain of the primary responsibility of a rheumatologist.

Seven percent down dramatically from 2012 when it was, twenty nine percent. They were much less likely to accept a new patient referral for fibromyalgia, down to less than a quarter, twenty four percent, versus sixty percent fourteen years ago. So who should treat it? According to these survey respondents, eighty nine percent felt back in 2012 that it was the primary care doctor. Now they've shifted away and said that now over half said pain management with about a third being in the primary care doctor domain.

But still the idea is, I think, more acceptance that it's significant disabling, maybe you should see a specialist in pain management, but even less of a thought then that this is our condition. And so I'm curious what other people think. I think it's hard because ultimately it is everyone's responsibility because whether we feel it's our responsibility or not, they are our patients, they turn to us, they will continue to be referred to us. And I think a lot of the primary care doctors, pain management doctors do not take ownership of this condition. Ultimately it's all of our responsibility.

It's not surprising that our attitudes have changed and yet therapeutic options have grown, and rheumatologists seem to know more about that. We tend to be the ones that do the clinical trials on this, but yet we don't want to manage it. The question really is who should manage it? At your centers and your academic centers. Bella, who manages fibromyalgia?

I think the problem with fibromyalgia is like no one is owning the patient or no one is owning the disease. Patients we do. So, if the patient it depends on who the patient comes in contact with first and I ideally think that whoever the patient sees, right? Like if primary care can diagnose fibromyalgia, they should treat it. If physiatrist sees them and can figure this out, they should treat them.

We also treat fibromyalgia, but I want to say that we don't have special clinics for fibromyalgia or, like, you know, sort of a fast track for it or whatever that we call it that they bucket into certain physicians. Everybody's... I think as a rheumatologist, everybody is seeing fibromyalgia to an extent, right, irrespective if you have a lupus only practice or whatever that you do, you are seeing this. So yeah, we don't have like a special bucket for it. With workforce shortages, I think everybody needs to pitch in, especially for a disease which is going to be so widespread.

Doctor. Yeah. So let's move on to our next one. Adela, you have a good one to talk about?

Yeah. On that same note from Eric, I'm going to go over abstract 20 eight-twenty four. So this is a cohort study that used data from the FORWARD, which is a national data bank for rheumatic diseases. And in this, they took over three hundred patients with lupus, and then they followed they did pretty much a cross sectional at baseline, and then they did a longitudinal follow-up, more or less a mean of three point seven years. In this study, what they were trying to evaluate was the presence of nosyplastic pain in different subgroups.

They actually classify the patients to minimal, meaning very minimal symptoms, type one symptoms, which are described more as inflammatory predominant, and these were pretty much based on the SLE activity questionnaire, which included arthritis, mucocutaneous, herositis, fever. Then they also added on another group was type two symptoms, which these were more like a polysymptomatic distress scale, so pretty much a combination of widespread pain plus symptom severity, and then the mixed pattern. So minimal type one, which was most inflammatory, type two, which was more nosyplastic, and then a mixed pattern, which was a combination of both. And what they found is pretty much at baseline, pretty much everything, most of the patients were minimal. Type one was very small.

Type two was also, I think it was like four percent, and then mix was thirty percent of the patients. But then over time, things change a little bit and this was very interesting. Over time, the symptoms of type two went up from four percent to thirty six percent, and when they went deeper into this group, in the mixed group, they found that not only the pain scale went up, but also depression rose over thirty percent, opioid use was almost forty nine percent in these patients. And then over time, they found that these patients were kind of like the type one and type two symptoms kind of like varied over time, but the patients that had the mixed pattern kind of like persisted over time. So that's what definitely caught my attention.

And when they were talking a little bit more about the type two symptoms, patients felt the description of fibromyalgia. Definitely, it's something that it was worth noting that over time in patients with lupus, not only the inflammatory symptoms may go down, but then the other symptoms that they develop are more in the nociplastic range.

If you hang out with lupus mavens, there's a lot to talk about in the lupus community, a lot of new therapies, a lot of excitement, B cell depletion, CAR T cell, whatever. But there's more and more discussion of this type two lupus, because it's largely been ignored. I think appropriately to better characterize it, to warn people as Adela has with this report, a warning that the longer you're managing these people, want to be looking for these, co conspirators that will increase nociplastic pain and add to your failure. What do you guys think?

I use the framework of type one, type two all the time. Discuss it with patients and it's something I know Doctor. Michele Petrie talks about a lot that you bring it to the patient and you say these are both the issues going on. They are both real. They are both affecting you significantly.

Type one, we need to focus on the medicines like hydroxychloroquine and immunosuppressive medicines. Type two, we need a different approach and let's break down, you know, your symptoms may not be affected with the traditional quote unquote lupus medications, but these are the treatment options that we use for type two, both pharmacologic and non pharmacologic. And I really like that framework because I think it is something that patients can grasp and understand.

Bella, what's your approach to these folks?

I think type two are the... These are the types which are the most difficult to treat. Sometimes at least when I teach fellows, I say that be careful about over immunosuppressing when you're trying to treat some other symptom essentially. Differentiating the symptoms or differentiating where it comes from is super important.

Doctor. Like to tie in with my abstract. This Type one, Type two nomenclature ties in well with difficult to treat RA where we talk about pura and nira, Nira being the type twos, noninflammatory refractory RA, and Pira is being persistent inflammatory refractory RA, type ones, if you will. My abstract is a RA study, from Ted Pincus, 1435. Pincus and coworkers, from Rush did a, asked the question, you know, if seventy five percent of the people that are assessed with RA using the MDHAC have zero to one swollen joints.

Why is it that, C. Remission and LDA is only achieved in forty five percent? That's a bit of a problem. And the answer to that question is that, over, forty five percent of patients will, on the MDHAC have evidence of anxiety, depression, and fibromyalgia, and saying that these are type two RAs. These are the nearest.

These are the difficult to treat. Obviously, this report is about how you can use the tool. My surveys from long ago that we presented at ACR, Jeff Curtis and I said that rheumatologists do, some kind of survey tool fifty four percent of the time. You know, rapid is probably the most common one, a little over a third of people using rapid. But the one that everyone really should be using is, you know, an...

A hack, MD hack, because you're gonna get much more information, especially if it's coupled with all the other review system stuff and, you know, medication reports and and ask specifically about working exercise and and whatnot. So the... You know, Pincus's report really was a pitch for, you know, use a tool, identify the problem because when depression complicates RA, mortality rates go up threefold. When, you know, fibromyalgia complicates RA, you know, drug responses are cut in half. I think it's really important message that was on this poster fourteen thirty five.

Don't you think that this is a chicken and an egg? We don't know if RA sensitized everything and now you have central pain or, you know, this is sort of ongoing. Yeah, you need to target both but differently.

Yeah. And I think, though, that it would obviously, we do target both. We've always thought that if I control the inflammatory disorder in front of me, then the patient will sleep better. The patient will have less secondary pain and whatever. But there still is this problem of residual pain in clinical trials when people are in remission, but they still have pain numbers that are high.

And, you know, there's a lot of literature in the last ten years about JAK inhibitors, maybe might be better at those at that kind of pain at that nocoplastic pain, although that makes nocoplastic makes no sense to us, but we don't know what we don't know. And however you can get, get them, and I do think being mindful of both. But I think that the instructive point about type one, type two lupus or a pyranera in RA or just the average, patient you're seeing in practice, regardless of diagnosis, is that if you pick up on these clues, then it'll shape your therapy, and you won't be barking up the wrong tree. So, let's start over. Our next round is going to be what I call quickies.

Let's do thirty second synopsis and, you know, minute and a half discussions at the most. Let's go back to, doctor Mehta.

Okay. So, this was, abstract fifteen fifty one, which is the Framingham Heart Study, again, the classic. But what they looked at is whether pain sensitization itself is partly heritable. So if your father had it or if your parents had it, do you have it? So they had around 3,000 participants from seven fifty ish families.

And what they did was pressure pain thresholds as well as conditioning pain modulation, which is basically they did a series of tests where you take pressure and poke it in patients. And at certain points, they'll be like, this hurts. And what they found is that pressure pain threshold was mostly heritable around 8% or was heritable only in eight percent, whereas conditioned pain modulation, so that's something that you acquire, was not. And joint pain was 21 heritable, so irrespective of the diagnosis, mind you. But basically there's a strong shared genetic correlation in that there is a huge biologic or genetic component with pain sensitization, particularly with widespread pain, non joint pain and nociplastic pain like fibromyalgia and fibromyalgia.

So, again, it's not about like, oh this person is reporting more pain versus not, especially in the male female context. It's known that, oh females report more pain, but maybe they're biologically more, you know, there's something in the biology which makes them do this more. Then this was a good, you know, sort of a well done study showing this, that there's genetic pathways talking about this.

So Adela and Eric, do you think from your patients that fibromyalgia is inherited?

So there, again, on that same lecture that I went, I would definitely not be surprised about the component of heritability. There's two pathways that have been described, kind of like, you know, the top to bottom and then the bottom up. So the top to bottom seems to be more kind of like this primary, which can be, you know, could be genetic component. And then the bottom up is the one that is pretty much like that was described more like a secondary, kind of related to inflammatory conditions or diseases. So I definitely think that the role play of these bottom up and top to bottom definitely have to play kind of like in the entire picture in patients with fibromyalgia.

Yeah, I think it definitely is multifactorial, and I think it's very hard to disentangle all of it. But we do see patients that have it as part of their family history, that they have a couple family members. And I think we know that there's biology and physiology that drives the nociceptive pain. And so I certainly would be surprised if there wasn't some kind of genetic component that our physiology is in so many different ways affected by our genes that as we learn more about the pandemic.

So it's easy to blame your mother and father and your genes than, you know, your lifestyle or anything else. But I think that the 800 pound gorilla in the bed is sleep. That's what's inheritable. People with bad sleep habits pass it on. Everybody in the family doesn't go to bed till 01:30.

You know, everybody in the family is... Sleeps until until 10:30 or eleven in the morning. And not everyone, but I think sleep is the most heritable feature that drives pain from my years of experience. And think that... I think we're compelled to think that why people have Weisser pain and fibromyalgia is so multifactorial because my goodness, aren't there complaints and stories and histories all over the place?

And you could shake a stick at many things as the cause for the problem with pain or the problem with sleep or the problem with fatigue. But I like reducing it to the thing that matters most. And to me, it's gonna be sleep. Let's move on. Eric, what's your shorty?

Yeah, abstract 2,547. I like when we get quick numbers that you could bring from a conference into conversations with patients and, the newest medication that we have out there now is the sublingual cyclobenzaprine that was recently FDA approved. There was the two studies, the relief, the resilient trials, fourteen weeks, and pulling that data, looking at number needed to treat, number needed to harm to bring that to the bedside for conversations. Number needed to treat, so number needed to treat meaning a 30% reduction in pain, was a number of seven. So one in seven patients that you start will have a benefit of at least 30% pain reduction.

Number needed to harm, harm meaning discontinuation due to adverse event. So that's twenty six. So one out of twenty six will stop it because of a side effect. Presumably others having more mild side effects, lot of oral discomfort with the sublingual formulation. It'll be one out of twenty six will stop it because they don't tolerate it.

So then they calculated a likelihood to be helped or harmed, balancing those two, the ratio of that. And that's 3.7 showing that there's almost a four time more likelihood of benefit than discontinuation due to side effects.

I was at a innovation theater where they presented the data and I asked the question, why is cyclobenzaprine sublingually better than cyclobenzaprine by pill? They both have a half life of thirteen hours. And in my practice, the main issues are dry mouth and hangover. But they said, that dry mouth and hangover is not really a problem. They didn't give me a number, but it wasn't a cause for discontinuation.

So, the... They said that it's because of the metabolite that, you know, it's the, the norecyclobenzaprine that gives you all the ugly stuff and they have less of that with the sublingual. But Eric, do you have a feel for the... The tolerability of this new preparation?

That's what they say is that it is metabolized differently and that in theory gives better tolerability. And obviously the oral never being approved for this condition, it is something that we do use. I think the biggest issue for me in terms of my real world practice with it is I prescribed it a few times and every other time it's been denied or approved at a price that has been drastically different than the oral. So my real world experience with it is low. But the theory is what you say is that it may be more manageable for patients.

Well, when I give oral, I just give it like in spots, like, you know, a month here and a month there. I'm not giving it daily. I don't think so.

So I have tried the sublingual because I was given samples And you have to be carefully selective of the population based on the study. I did read the study. The mains, I think it was like, I remember we affirmed maybe, it was like a couple of years ago. They excluded patients that were complaining of pain more than 10. So when you ask your fibromyalgia patients, what's your level of pain?

And then it seemed more like the greatest benefit was on the ones that had kind of like poor sleep. So in that population, when the pain is not so bad that they really have really bad sleep, I have used some of them and I've had mixed results, I have to say. One of the things that I have noticed from these patients, definitely they have not been complaining of the daily fatigue, but two of them definitely have complained of the numbness in the mouth.

Interesting. Again, the drug is in the sublingual form, two point six, I think, the dose either one or two. You start with one, you go to two, and you look at tolerability. So all right, Adela, what's your shorty?

So my shorty is abstract thirteen thirty seven, and these, I evaluated the prevalence of nociplastic pain in a cohort with axSpA, and they took eighty three patients, fifty percent of them were female, and then they earned the well evaluation for the presence of nocciplastic pain. Thirty two point five percent of patients were positive for nocciplastic pain, and they also did the fibromyalgia questionnaire, which correlated the high disease activity with the ASDACRP. So in a nutshell, it's very important when we assess activity in our patients with axSpA as well, that there's high prevalence of nociplastic pain, and we have to be very careful when we are adjusting therapies in our patients.

So mine ties in fairly well with that. My short one is the upstand study presented by, Philip Meiss, 347. It was upadacitinib in axial spondyloarthritis patients. Patients that were enrolled in the study, it was a few 100, I think, were excluded if they had fibromyalgia. When they analyzed the data, one of the things that...

One of the secondary outcome measures they looked at was widespread pain index, a WPI. You know? And, you know, a WPI of greater than six is said to be pretty indicative of nosaplastic pain. It turns out all these people that were enrolled with axSpA without fibromyalgia, forty nine percent of them had a WPI greater than six, which is number one to say this is a, a prevalent problem that even when you exclude for it, even though it's... The patient's unaware that they have fibromyalgia or the doctor hasn't diagnosed it or it's not in the chart, doesn't mean it's not operative, for reasons that were said already in the session that, you know, you're treating one thing, who's to say it won't come up later on or be, you know, a minor player that doesn't come out until you've controlled the inflammation and the sacroiliitis, for instance.

But the thing about that study also was that they treated them with upadacitinib, and it looked like the effects on pain in that trial, and this was low back pain indices and, inflammatory indices, were certainly contributed to by the WPI. And that use of RINVOQ seemed to have a short term effect that the WPI might have improved early on in the first few weeks. But then when you looked out at week 52, it was less important. There, you're now looking probably more at week week twenty four and fifty two. You're looking at the effects of JAK inhibition on spondylitis, and the WPI isn't playing as big a role or it's not differentiating between different cohorts.

Anyway, the point is it's there. Adela's number was thirty four percent, the upstand was forty nine percent. It's a a significant number of folks. So... Alright.

I wanna thank our our panel for these great, choices and for covering fibromyalgia at the meeting. There was a lot, that we presented on the website. We hope that you'll look at the other podcasts on this, and the many videos that we did on this. Tune in for more topic panels on RheumNow post ACR. Thanks, folks.

Thank you.

Thank you.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×